



Influenza Work Group Considerations and Proposed 2019-20 Season Recommendations

Lisa Grohskopf, MD, MPH

Influenza Division, CDC

Advisory Committee on Immunization Practices

June 27, 2019

Acknowledgments

Influenza Division

Elif Alyanak
Noreen Alabi
Lenee Blanton
Lynnette Brammer
Joe Bresee
Alicia Budd
Jessie Chung
Scott Epperson
Jill Ferdinands
Brendan Flannery
Alicia Fry
Dan Jernigan
Krista Kniss
Natalie Kramer
Manish Patel
Melissa Rolfes
Jerry Tokars
Tim Uyeki

Immunization Safety Office

Karen Broder
Frank Destefano
Penina Haber
Tom Shimabukuro

Immunization Services Division

Sam Graitcer
Andrew Kroger
Amy Parker Fiebelkorn
Jeanne Santoli

2019-20 Core Recommendation (Unchanged)

- Annual influenza vaccination is recommended for all persons aged 6 months and older who do not have contraindications

2019-20 Primary Updates: Vaccine Composition

■ Trivalent Vaccines

- A/Brisbane/02/2018 (H1N1)pdm09-like virus—*updated*
- A/Kansas/14/2017 (H3N2)-like virus—*updated**
- B/Colorado/06/2017-like virus (Victoria lineage)

■ Quadrivalent Vaccines

- Above three, plus B/Phuket/3073/2013-like virus (Yamagata lineage)

** Selection of H3N2 component delayed until March 21, 2019*

Projected Influenza Vaccine Supply (2019-20 Season)

Maximum projected supply: 162-169M*	
Manufacturer	Distribution estimated to begin
AstraZeneca	Early September
GSK	Mid August
Sanofi Pasteur	Late August/Early September
Seqirus	Mid August

* Information presented 5/16/19 at the National Adult Immunization and Influenza Summit, confirmed June 2019. The estimate aggregates information across manufacturers about potential maximum production for the season and could change based on production yield, lot release, and demand for vaccine.

2019-20 Primary Updates: Licensure Changes

- **Licensure changes for Afluria Quadrivalent and Fluzone Quadrivalent**
- **Four IIVs expected to be available for ages 6 through 35 months**
- **Dose volumes differ:**
 - Fluarix Quadrivalent (IIV4, GSK) 0.5 mL
 - FluLaval Quadrivalent (IIV4, ID Biomedical Corp/GSK) 0.5 mL
 - Fluzone Quadrivalent (IIV4, Sanofi Pasteur)* 0.25 mL or 0.5 mL
 - Afluria Quadrivalent (IIV4, Seqirus)* 0.25 mL
- **New table added to Statement summarizing dose volumes**
- **Dose volume for persons aged ≥ 3 years is 0.5mL for all IIVs**

2019-20 ACIP Guidance Updates:

- **Timing of vaccination:**
 - Language concerning July/August vaccination moved to top paragraph

“For those requiring only one dose for the season, early vaccination (i.e., in July and August) is likely to be associated with suboptimal immunity before the end of the influenza season, particularly among older adults”
- **Groups that should be focus of efforts if supply is limited:**
 - Language describing health care personnel made consistent with 2011 ACIP Recommendations for the Immunization of Health Care Personnel
- **Vaccine doses needed for children aged 6 months through 8 years:**
 - Clarified to indicate that 8-year-olds needing two doses should receive second dose even if they turn 9 years of age between dose 1 and dose 2 (consistent with AAP guidance)
- **Concomitant receipt of two vaccines containing novel adjuvants:**
 - Notes that given limited safety data, non-adjuvanted influenza vaccines may be considered when giving another vaccine containing a novel adjuvant; vaccination should not be delayed if a specific product is not available

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

